K
Karen L. Reckamp
Researcher at Cedars-Sinai Medical Center
Publications - 304
Citations - 21352
Karen L. Reckamp is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 51, co-authored 259 publications receiving 17234 citations. Previous affiliations of Karen L. Reckamp include City of Hope National Medical Center & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
Julie R. Brahmer,Karen L. Reckamp,Paul Baas,Lucio Crinò,Wilfried Eberhardt,Elena Poddubskaya,Scott J. Antonia,Adam Pluzanski,Everett E. Vokes,Esther Holgado,David M. Waterhouse,Neal Ready,Justin F. Gainor,Osvaldo Arén Frontera,Libor Havel,Martin Steins,Marina Chiara Garassino,Joachim G.J.V. Aerts,Manuel Domine,Luis Paz-Ares,Martin Reck,Christine Baudelet,Christopher T. Harbison,Brian Lestini,David R. Spigel +24 more
TL;DR: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level.
Journal ArticleDOI
Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology
David S. Ettinger,Douglas E. Wood,Dara L. Aisner,Wallace Akerley,Jessica Bauman,Lucian R. Chirieac,Thomas A. D'Amico,Malcolm M. DeCamp,Thomas J. Dilling,Michael C. Dobelbower,Robert C. Doebele,Ramaswamy Govindan,Matthew A. Gubens,Mark Hennon,Leora Horn,Ritsuko Komaki,Rudy P. Lackner,Michael Lanuti,Ticiana A. Leal,Leah J. Leisch,Rogerio Lilenbaum,Jules Lin,Billy W. Loo,Renato Martins,Gregory A. Otterson,Karen L. Reckamp,Gregory J. Riely,Steven E. Schild,Theresa A. Shapiro,James P. Stevenson,Scott J. Swanson,Kurt Tauer,Stephen C. Yang,Kristina M. Gregory,Miranda Hughes +34 more
TL;DR: This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastasis disease.
Journal ArticleDOI
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
Leora Horn,David R. Spigel,Everett E. Vokes,Esther Holgado,Neal Ready,Martin Steins,Elena Poddubskaya,Hossein Borghaei,Enriqueta Felip,Luis Paz-Ares,Adam Pluzanski,Karen L. Reckamp,Marco Angelo Burgio,Martin Kohlhaeufl,David M. Waterhouse,Fabrice Barlesi,Scott J. Antonia,Oscar Arrieta,Jérôme Fayette,Lucio Crinò,Naiyer A. Rizvi,Martin Reck,Matthew D. Hellmann,William J. Geese,Ang Li,Anne Blackwood-Chirchir,Diane Healey,Julie R. Brahmer,Wilfried Eberhardt +28 more
TL;DR: Nivolumab provides long-term clinical benefit and a favorable tolerability profile compared with docetaxel in previously treated patients with advanced NSCLC and is reported on in a pooled analysis of the two studies.
Journal ArticleDOI
Prostaglandin E2 Induces FOXP3 Gene Expression and T Regulatory Cell Function in Human CD4+ T Cells
Felicita Baratelli,Ying Lin,Li Zhu,Seok-Chul Yang,Nathalie Heuzé-Vourc'h,Gang Zeng,Karen L. Reckamp,Mariam Dohadwala,Sherven Sharma,Steven M. Dubinett +9 more
TL;DR: PGE2 enhances the in vitro inhibitory function of human purified CD4+CD25+ T reg cells and induces a regulatory phenotype in CD4-CD25− T cells, the first report indicating that PGE2 can modulate FOXP3 expression and T reg function in human lymphocytes.
Journal ArticleDOI
Non-small cell lung cancer: Clinical practice guidelines in oncology
David S. Ettinger,Wallace Akerley,Gerold Bepler,Matthew G. Blum,Andrew C. Chang,Richard T. Cheney,Lucian R. Chirieac,Thomas A. D'Amico,Todd L. Demmy,Apar Kishor Ganti,Ramaswamy Govindan,Frederic W. Grannis,Thierry Jahan,Mohammad Jahanzeb,David H. Johnson,Anne Kessinger,Ritsuko Komaki,Feng Ming Kong,Mark G. Kris,Lee M. Krug,Quynh-Thu Le,Inga T. Lennes,Renato Martins,Janis P. O'Malley,Raymond U. Osarogiagbon,Gregory A. Otterson,Jyoti D. Patel,Katherine M.W. Pisters,Karen L. Reckamp,Gregory J. Riely,Eric M. Rohren,George R. Simon,Scott J. Swanson,Douglas E. Wood,Stephen C. Yang +34 more
TL;DR: The NCCN Clinical Practice Guidelines in Oncology for Small Cell Lung Cancer (SCLC) focus on extensive-stage SCLC because it occurs more frequently than limited-stage disease as discussed by the authors.